A compound of general formula wherein R 1 is hydrogen or (C 1 -C 4)alkyl; and wherein R 2 is selected from the group consisting of tetrahydropyranyl, oxaspiroheptanyl, pyrrolidinyl and piperidinyl; wherein said pyrrolidinyl and piperidinyl are optionally substituted with one or more substituents independently selected from R 4; and wherein R 4 is selected from the group consisting of -C (C 1 -C 4)alkyl, (C 1 -C 4)alkyl, - S 2 R X, -S 2 NR a R b, -C O(C 1 -C 6)alkyl, -C NR a R b and -(C 1 -C 4)alkyl-C NR a R b; and wherein R a and R b are independently selected from the group consisting of hydrogen, (C 1 -C 4)alkyl and halo(C 1 -C 4)alkyl, or R a and R b may together with the nitrogen atom to which they are attached form a -membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more (C 1 -C 4)alkyl; and wherein R 3 is selected from the group consisting of (C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, (C 1 -C 4)alkyl(C 3 -C 6)cycloalkyl, halo(C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, (C 1 -C 6)alkyl(C 1 -C 6)alkoxy, halo(C 1 -C 4)alkyloxy, membered heterocycloalkyl, (C 1 -C 4)alkyl membered heterocycloalkyl, membered heteroaryl, (C 1 -C 4)alkyl membered heteroaryl, aryl and (C 1 -C 4)alkylaryl; wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl and aryl are optionally substituted with one or more substituents independently selected from R 5; and wherein R 5 is selected from the group consisting of halogen, cyano, hydroxyl, (C 1 -C 4)-alkyl, halo(C 1 -C 4)alkyl, halo(C 1 -C 4)alkyloxy, OR x, -SR x, -S 2 R X, -S 2 NR a R b, -C R x, - C (OR x), and -C NR a R b; and wherein R x is selected from the group consisting of (C 1 -C 4)alkyl, (C 3 -C 6)cycloalkyl, and heterocycloalkyl; and wherein S* represent a chiral sulphur atom; and pharmaceutically acceptable salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates and solvates thereof. wherein R 1 is hydrogen or (C 1 -C 4)alkyl; and wherein R 2 is selected from the group consisting of tetrahydropyranyl, oxaspiroheptanyl, pyrrolidinyl and piperidinyl; wherein said pyrrolidinyl and piperidinyl are optionally substituted with one or more substituents independently selected from R 4; and wherein R 4 is selected from the group consisting of -C (C 1 -C 4)alkyl, (C 1 -C 4)alkyl, - S 2 R X, -S 2 NR a R b, -C O(C 1 -C 6)alkyl, -C NR a R b and -(C 1 -C 4)alkyl-C NR a R b; and wherein R a and R b are independently selected from the group consisting of hydrogen, (C 1 -C 4)alkyl and halo(C 1 -C 4)alkyl, or R a and R b may together with the nitrogen atom to which they are attached form a -membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more (C 1 -C 4)alkyl; and wherein R 3 is selected from the group consisting of (C 1 -C 6)alkyl, (C 3 -C 6)cycloalkyl, (C 1 -C 4)alkyl(C 3 -C 6)cycloalkyl, halo(C 1 -C 6)alkyl, (C 1 -C 6)alkoxy, (C 1 -C 6)alkyl(C 1 -C 6)alkoxy, halo(C 1 -C 4)alkyloxy, membered heterocycloalkyl, (C 1 -C 4)alkyl membered heterocycloalkyl, membered heteroaryl, (C 1 -C 4)alkyl membered heteroaryl, aryl and (C 1 -C 4)alkylaryl; wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl and aryl are optionally substituted with one or more substituents independently selected from R 5; and wherein R 5 is selected from the group consisting of halogen, cyano, hydroxyl, (C 1 -C 4)-alkyl, halo(C 1 -C 4)alkyl, halo(C 1 -C 4)alkyloxy, OR x, -SR x, -S 2 R X, -S 2 NR a R b, -C R x, - C (OR x), and -C NR a R b; and wherein R x is selected from the group consisting of (C 1 -C 4)alkyl, (C 3 -C 6)cycloalkyl, and heterocycloalkyl; and wherein S* represent a chiral sulphur atom; and pharmaceutically acceptable salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates and solvates thereof.